NovaBiotics announces its latest peer-reviewed publication describing data confirming the stand-out properties of Novexatin® (NP213), NovaBiotics’ brush-on treatment for fungal nail infection (onychomycosis).
The paper, “NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile” will appear in the next issue of Medical Mycology, the official journal of the International Society for Human and Animal Mycology.
Deborah O’Neil, CEO of NovaBiotics, said, “We are now considering the most appropriate route to market for Novexatin. With its game-changing safety and efficacy profile and its novel mechanism of action, it provides a solution to a common condition and significant global market that cannot come soon enough for tens of millions of onychomycosis sufferers”.
The full article can be accessed here NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile